Prof. Knop gives an overview of potential mechanisms of action of GLP-1RAs to explain observed effects on glycemia, body weight, blood pressure and blood lipids.
Prof. Deanfield explains why these are exciting times for the management of CVD in patients with diabetes and also in those without diabetes.
Prof. Sattar shows that CV risk is heterogenous in patients with diabetes, and explains why new diabetes drugs, such as GLP-1RAs, are recommended for patients with diabetes and CV risk.